[Catheter ablation : Developments and technique selection]

Area of Science:

• Cardiology
• Electrophysiology
• Medical Technology

Background:

• Atrial fibrillation (AF) is the most common cardiac arrhythmia and a significant risk factor for cardiovascular events.
• Current guidelines recommend rhythm-controlling therapy primarily for symptomatic AF, with a Class IIa recommendation for catheter ablation in paroxysmal AF.
• Emerging evidence suggests advantages of early rhythm control over rate control and catheter ablation over antiarrhythmic drugs (AADs).

Purpose of the Study:

• To review current and emerging catheter ablation techniques for atrial fibrillation (AF).
• To compare the efficacy and safety of radiofrequency ablation, cryoablation, high-power short duration ablation, and pulsed field ablation.
• To highlight the potential of novel ablation strategies in improving patient outcomes and reducing procedure-related risks.

Main Methods:

• Review of current literature on catheter ablation techniques for AF.
• Comparison of pulmonary vein isolation (PVI) using radiofrequency, cryoablation, high-power short duration ablation, and pulsed field ablation.
• Analysis of procedural outcomes, including recurrence rates, procedure times, reintervention rates, and adverse events.

Main Results:

• Cryoablation is gaining importance as a first-line therapy for paroxysmal AF, showing shorter procedure times and improved quality of life.
• High-power short duration ablation demonstrates lower recurrence rates and shorter procedure times compared to traditional radiofrequency ablation.
• Pulsed field ablation, a novel technique, shows promise for isolated myocardial cell damage without collateral effects, based on preclinical data.

Conclusions:

• Catheter ablation techniques for AF are advancing, with cryoablation and high-power short duration ablation offering benefits over traditional methods.
• Pulsed field ablation represents a promising new frontier, potentially minimizing collateral damage, though further randomized trials are necessary for validation.
• Optimizing AF management through innovative ablation strategies is crucial for improving patient outcomes and reducing cardiovascular event risk.